YOKOHAMA, Japan, May 7, 2026
CoreTissue BioEngineering announced the initiation of the randomized controlled cohort in its ongoing clinical trial evaluating CT-ACL001, an investigational tissue-regenerative ligament therapy for patients undergoing anterior cruciate ligament (ACL) reconstruction surgery. The milestone follows the successful completion of the safety evaluation phase of the company’s earlier safety cohort study, allowing the program to transition into a larger controlled clinical evaluation designed to assess both safety and efficacy against current surgical standards. The multicenter trial will compare CT-ACL001 with conventional ACL reconstruction procedures using a patient’s own hamstring tendon, which remains the current standard of care for ACL injuries.
The randomized controlled portion of the study is expected to play a major role in determining the future regulatory pathway for the company’s regenerative orthopedic platform in Japan. The study will be conducted across six leading Japanese university hospitals, including Tokyo Women’s Medical University Hospital, Hirosaki University Hospital, Hiroshima University Hospital, Hokkaido University Hospital, Juntendo University Hospital, and Kobe University Hospital. The company stated that the trial officially began enrollment activities in May 2026 and represents a significant advancement in regenerative medicine approaches targeting sports-related orthopedic injuries.
Randomized Clinical Trial Expands Evaluation of CT-ACL001
The clinical study is evaluating the investigational medical device “Tissue Regenerative Ligament” (CT-ACL001), which is designed to support regeneration of damaged ACL tissue while potentially reducing some limitations associated with conventional tendon graft procedures. According to the company, the randomized cohort will enroll 38 patients receiving CT-ACL001 reconstruction therapy and 19 patients receiving standard autologous hamstring tendon reconstruction surgery as the control group. The primary objective of the study is to evaluate whether CT-ACL001 can demonstrate favorable safety outcomes alongside meaningful clinical efficacy in restoring knee stability and function following ACL injury.
ACL injuries are among the most common serious sports-related orthopedic injuries globally and frequently affect athletes and physically active individuals, often requiring surgical intervention followed by lengthy rehabilitation periods. Traditional ACL reconstruction surgeries rely on harvesting tendons from the patient’s own body, which can create additional surgical trauma and may contribute to donor-site complications. CoreTissue BioEngineering’s regenerative approach aims to provide an alternative strategy capable of improving tissue healing while reducing some of the procedural limitations associated with existing reconstruction methods.
Advertisement
Early Safety Results Support Continued Clinical Advancement
CoreTissue BioEngineering confirmed that safety evaluations from the initial safety cohort were completed successfully, allowing progression into the randomized phase of the trial. Initial findings from the safety portion of the study are scheduled to be presented later this month at the 22nd Congress of the European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA), one of the major global scientific meetings focused on orthopedic sports medicine and knee surgery. The presentation will be delivered by Dr. Masafumi Ito of the Department of Orthopedic Surgery at Tokyo Women’s Medical University.
The company believes the transition into randomized clinical evaluation represents an important validation milestone for its tissue regeneration platform and may help establish clinical evidence supporting future commercialization efforts. Following completion of the trial’s primary endpoint analysis, CoreTissue BioEngineering plans to pursue manufacturing and marketing approval in Japan for CT-ACL001 as a regenerative orthopedic medical device. The development program is also being supported through funding from the Japan Agency for Medical Research and Development (AMED), highlighting growing institutional interest in regenerative technologies aimed at improving outcomes for musculoskeletal injuries.
Regenerative Orthopedic Technologies Gain Industry Attention
The advancement of CT-ACL001 reflects increasing global interest in regenerative medicine approaches designed to improve orthopedic surgery outcomes and reduce recovery burdens for patients. While ACL reconstruction remains one of the most commonly performed orthopedic procedures worldwide, researchers and medical technology developers continue exploring biologic and tissue-engineering solutions capable of enhancing ligament healing and restoring native tissue function more effectively than conventional graft-based procedures.
Regenerative ligament technologies are attracting attention because of their potential to shorten rehabilitation timelines, reduce complications associated with tendon harvesting, and improve long-term joint stability. Industry observers are closely monitoring clinical developments in tissue-engineered orthopedic products as the regenerative medicine sector expands beyond cell therapies into structurally engineered implantable solutions. With randomized controlled evaluation now underway, CoreTissue BioEngineering’s CT-ACL001 program may provide important clinical insight into the future role of regenerative ligament reconstruction technologies within sports medicine and orthopedic surgery markets.
Source: CoreTissue BioEngineering press release
